Considerations for use of blood-based biomarkers in epidemiologic dementia research

Abstract

Abstract Dementia represents a growing public health burden with large social, racial, and ethnic disparities. The etiology of dementia is poorly understood, and the lack of robust biomarkers in diverse, population-representative samples is a barrier to moving dementia research forward. Existing biomarkers and other pathology measures derived from neuropathology, neuroimaging, and cerebrospinal fluid samples, are commonly collected in predominantly White and highly-educated samples drawn from academic medical centers in urban settings. Blood-based biomarkers are non-invasive and less expensive, offering promise to expand our understanding of the pathophysiology of dementia, including in participants from historically-excluded groups. Although largely not yet FDA-approved or used in clinical settings, blood-based biomarkers are increasingly included in epidemiologic studies on dementia. Blood-based biomarkers in epidemiologic research may allow the field to more accurately understand the multifactorial etiology and sequence of events that characterize dementia-related pathophysiological changes. As blood-based dementia biomarkers continue to be developed and incorporated into research and practice, we outline considerations for using them in dementia epidemiology, and illustrate key concepts with Alzheimer’s Disease Neuroimaging Initiative (2003-present) data. We focus on measurement, including both validity and reliability, and on the use of dementia blood-based biomarkers to promote equity in dementia research and cognitive aging.